Skip to content

Commercial & Clinical Landscape (2024–2026)

2024–2026 is the tipping point for BCI commercialization. This chapter is organized by company — because since 2024 the most important narrative unit in the BCI field is no longer "which algorithm is better" but "which company, in which country, via which pathway, got approval when, and how many patients have been implanted."

Where this chapter sits. It maps everything you learned in Chapters 1–10 (electrodes / decoders / I2A / writing / manifolds) onto specific company product lines. After reading this chapter, you can revisit Neuralink press events, Synchron COMMAND papers, or the Neuracle 2026-03 NMPA approval and instantly identify which layer of the stack each news item touches, what it solves, and what it still lacks. This chapter also doubles as a quick reference for evaluating BCI investment, clinical partnerships, and regulatory pathways.

Recommended reading order. Read the five sections in order: invasive → minimally invasive → diverse routes → China ecosystem → regulation. Neuralink PRIME Study is the flagship for invasive flexible-thread electrodes — see how it grounds the minimally invasive interface (Chapter 03), the intent decoding (Chapter 06), and ReFIT calibration (Chapter 04) in one real product. Next, Synchron Stentrode shows how the endovascular route trades lower bandwidth for shorter surgery and reversibility. Precision / Paradromics / Blackrock covers the other two FDA-approved 2025 paths. China BCI Ecosystem zooms in on Neuracle × Tsinghua NEO (the world's first commercialized BCI, NMPA approved 2026-03) along with StairMed and NeuraMatrix. Finally, Regulatory Pathways FDA / NMPA ties the chapter's compliance backdrop together.

This chapter covers:

评论 #